Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up
Recruiting now · Phase 4
Conditions studied: HIV Infections
In brief
This is a phase 4, randomized, controlled, open-label, single-center clinical trial conducted at the Hospital de Infectología, National Medical Center "La Raza." The study employs a non-inferiority design with follow-up assessments at 24 and 48 weeks. The study will enroll 156 PLWH aged ≥18 years who are on ART with BIC/FTC/TAF or DTG/3TC/ABC and have maintained virological suppression (HIV-1 RNA \<50 copies/mL) for at least 48 weeks. Participants will be randomized in a 2:1 ratio: 104 to switch to DTG/3TC and 52 to continue their current regimen (control group).
Key facts
- Study ID
- NCT07138144
- Run by
- José Antonio Mata Marín
- People needed
- 156
- Starts
- 2025-07-12
- Expected to finish
- 2026-07-30
- Last updated by the study team
- 2025-08-22
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- PLWH aged over 18 years.
- Virologically suppressed for at least 48 weeks prior to study enrollment.
- On ART with Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) or Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC).
- No history of virologic failure.
- Willing to participate in the study.
- Signed written informed consent.
- HIV-1 RNA <50 copies/mL within 4 weeks prior to randomization.
- eGFR by CKD-EPI ≥60 mL/min.
You may not qualify if…
- Pregnant or breastfeeding patients.
- Known allergies to any component of the antiretroviral regimens.
- Coinfection with hepatitis B and/or hepatitis C virus.
- Concomitant medications that interact with any component of the ART regimens.
- Diagnosis of malignancy prior to randomization.
- Use of recreational drugs with anorexigenic potential (crystal meth, methamphetamines, cocaine) within 60 days prior to randomization.
Where it is running
- Hospital de Infectología, Centro Médico Nacional La Raza — Mexico City, Mexico City, Mexico (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.